- Wedbush's Liana Moussatos has started coverage on La Jolla Pharma (NASDAQ:LJPC) with an Outperform and $27 PT.
- Moussatos sees a "70% probability of a positive outcome" for a Phase 2a trial of La Jolla's GCS-100 drug in March, and thinks the drug could see peak annual sales of $1B.
La Jolla Pharma +22.4% AH. Wedbush starts at Outperform.
Recommended For You
About INVA Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| INVA | - | - |
| Innoviva, Inc. | ||